Blockchain technology, once the domain of cryptocurrency enthusiasts and tech visionaries, is now making waves across a spectrum of industries, from finance to pharmaceuticals. In recent days, two new reports—one from MarketBeat and another from QY Research Inc.—have spotlighted the remarkable momentum behind blockchain’s adoption in both the stock market and the pharmaceutical sector, offering a window into how this once-niche technology is changing the rules of the game for investors and industry leaders alike.
On February 12, 2026, MarketBeat identified seven blockchain stocks that investors should keep an eye on: Core Scientific, Figure Technology Solutions, Globant, Bitdeer Technologies Group, Digi Power X, Nukkleus, and Core Scientific (the latter appearing twice due to slightly different ticker symbols). These companies had the highest dollar trading volume among blockchain stocks over the past several days, reflecting growing interest in blockchain’s commercial potential.
But what exactly are blockchain stocks? According to MarketBeat, these are shares of publicly traded companies whose primary business involves developing, supporting, or leveraging blockchain technology. This could mean anything from building blockchain platforms and mining cryptocurrencies to providing secure digital wallets or crafting enterprise-level distributed ledger solutions. For investors, these stocks offer a way to gain exposure to the growth of blockchain applications without directly buying cryptocurrencies—a tempting proposition, though not without its own set of risks tied to company performance and regulatory changes.
Core Scientific, for example, stands out as a digital asset mining powerhouse in North America. The company operates through two main segments: Mining and Hosting. It not only mines digital assets for its own accounts but also offers hosting services for other major bitcoin miners, handling everything from deployment and monitoring to troubleshooting and maintenance of mining equipment. This dual approach allows Core Scientific to serve both itself and a growing roster of institutional clients seeking reliable blockchain infrastructure and software solutions.
Figure Technology Solutions is another name on the list, and its ambitions are no less grand. Figure is building the future of capital markets using blockchain-based technology. Its proprietary platform powers next-generation lending, trading, and investing activities, with a focus on consumer credit and digital assets. The company touts its blockchain ledger’s ability to improve speed, efficiency, standardization, and liquidity—key attributes for anyone looking to modernize financial markets.
Globant, meanwhile, takes a broader approach as a technology services provider with a global reach. The company’s offerings span blockchain, cloud computing, cybersecurity, artificial intelligence, digital experience, the metaverse, and enterprise technology solutions. Its client base includes giants like AWS, Google Cloud, Microsoft, Oracle, SalesForce, SAP, and ServiceNow, making it a major player in the digital transformation sweeping industries worldwide.
Bitdeer Technologies Group specializes in blockchain and computing, providing hash rate sharing solutions like Cloud hash rate and a hash rate marketplace. Its one-stop hosting solutions for mining machines include deployment, maintenance, and management, and the company also mines cryptocurrencies for its own account. Digi Power X, incorporated in 2017 and headquartered in Toronto, focuses exclusively on digital currency mining within the United States.
Nukkleus, rounding out the MarketBeat list, is a financial technology firm offering blockchain-enabled solutions worldwide. Its main focus is the retail foreign exchange trading industry, but it also provides cross-border payment and transaction services, as well as blockchain-enabled financial solutions for institutional investors. The breadth of these companies’ operations underscores the versatility of blockchain technology and its growing role in global commerce.
Yet, the excitement around blockchain is not limited to finance and tech. On February 13, 2026, QY Research Inc. released a landmark report projecting explosive growth for blockchain in the pharmaceutical sector. According to the report, the global Blockchain In Pharmaceutical market—valued at US$ 6.98 billion in 2025—is expected to soar to US$ 144.64 billion by 2032, boasting a staggering compound annual growth rate (CAGR) of 55.0% from 2026 through 2032.
What’s driving this surge? Blockchain in pharmaceuticals refers to the use of blockchain technology to securely store personal health information and provide healthcare providers with broader, yet secure, access to patient data. The technology’s application ensures that sensitive information is protected through encrypted signatures while enabling seamless sharing among authorized parties.
Private blockchains dominate the pharmaceutical sector, holding about 91% of the market share, according to QY Research Inc. The largest application by far is supply chain logistics, which accounts for nearly 69% of the market. This makes sense when you consider the sector’s pressing needs: supply chain transparency, counterfeit drug prevention, regulatory compliance, improved drug recall management, and enhanced data security.
Blockchain’s immutable and decentralized ledger brings end-to-end visibility to the pharmaceutical supply chain, helping combat counterfeit drugs—a problem that costs the industry billions each year and poses serious risks to patient safety. By making every transaction tamper-proof and traceable, blockchain ensures that drugs can be tracked from manufacturer to end-user, reducing the chances of fakes slipping through the cracks.
The technology also streamlines regulatory compliance, providing auditable records for agencies like the FDA and EMA. In the event of a drug recall, blockchain enables rapid identification and tracking of affected batches, minimizing harm to patients and financial losses for manufacturers. And with cyber threats on the rise, blockchain’s cryptographic protections offer a bulwark against data breaches, safeguarding patient records and clinical trial data.
The competitive landscape in the pharmaceutical blockchain market is fierce, with major players such as IBM, AWS, Microsoft, SAP, Chronicled, Embleema, FarmaTrust, and Guardtime Federal all vying for dominance. These companies are investing heavily in research and development, mergers and acquisitions, and strategic partnerships to expand their market presence and accelerate innovation.
Regionally, the QY Research report covers North America, Europe, Asia Pacific, Central and South America, and the Middle East & Africa, offering detailed forecasts through 2032. For executives, investors, and product managers, the report is a treasure trove of insights, supporting strategic decision-making and helping stakeholders identify high-growth segments and expansion opportunities.
It’s not just a story of technology—it’s a story of transformation. Blockchain is no longer just a buzzword or a speculative investment vehicle. It’s a foundational technology reshaping industries as diverse as finance and healthcare, offering new avenues for transparency, security, and efficiency. With billions of dollars at stake and the promise of safer, more reliable systems, blockchain’s rise is one that investors and industry leaders alike can’t afford to ignore.